Details for Patent: 5,707,608

Scope and claims dissection of US Patent 5,707,608: liposomal hydro-monobenzoporphyrin photosensitizers (EPG/DMPC) with <300 nm particle size—plus US patent landscape and generic entry risk

US Patent 5,707,608 claims a tightly bounded liposome manufacture process and the resulting liposomal composition for delivering a specific photosensitizer class (hydro-monobenzoporphyrin, “Gp”) in a defined phospholipid system (EPG + DMPC) to achieve sub-300 nm particles by hydrate-at-below-Tg and post-processing below Tg. The claim set has two levels of restriction: (1) process/operating windows (molar ratios, solvent removal, temperature relative to glass transition, size endpoints) and (2) chemical identity of the photosensitizer (formula coverage for Gp variants including BPD-MA) plus optional excipient constraints in aqueous hydration (disaccharide/polysaccharide such as lactose or trehalose).

What patents protect US 5,707,608’s liposomal Gp/EPG/DMPC method and composition?

Direct protection in US 5,707,608

• Method claims 1–16: manufacture method for liposomes comprising hydro-monobenzoporphyrin (Gp) plus EPG/DMPC phospholipids, with process constraints that narrow patent scope to a specific preparation route and operating windows.
• Composition claims 17–24: liposomal composition with defined particle size range and defined lipid mixture and photosensitizer ratio, plus Gp structural coverage and particle-size cutoffs.

Functional takeaway US 5,707,608 is not a broad “liposomes + photosensitizer” patent. It is a “make sub-300 nm Gp liposomes with EPG/DMPC using hydrate below Tg, then size-reduce below Tg, optionally with specific sugars” patent.

Core claim elements that define infringement boundaries

Across independent claims (1 for method; 17 for composition), these limitations are gating:

1. Photosensitizer identity

   • “hydro-monobenzoporphyrin photosensitizer” with formula coverage in dependent claim 8 (and independent claim language via claims 1/17 plus claim 19 for composition specificity).
   • BPD-MA is explicitly called out in dependent claim 12 (method) and claim 23 (composition).

2. Lipid mixture identity

   • Egg phosphatidyl glycerol (EPG) and dimyristoyl phosphatidyl choline (DMPC) as the phospholipid mixture.
   • Dependent claims do not add other lipids; independent claims require the EPG + DMPC mixture.

3. Stoichiometric ratio

   • At least 1:7.0 molar ratio of photosensitizer:phospholipid (method claim 1; composition claim 17).
   • Dependent narrows to about 1:8.0 or more phospholipid (method claim 2; composition claim 18).

4. Process sequence and temperature relative to Tg

   • Step (a): combine photosensitizer and phospholipids in organic solvent at specified molar ratio.
   • Step (b): remove solvent to form photosensitizer:phospholipid complex.
   • Step (c): hydrate below the glass transition temperature of the photosensitizer:phospholipid complex to form coarse liposomes.
   • Step (d): homogenize/reduce particle size to <300 nm at a temperature below the glass transition temperature of the complex.

5. Particle size endpoint

   • Below about 300 nm (method claim 1; composition claim 17 specifies 150–300 nm).
   • Dependent tightens: <250 nm (claim 15), <220 nm (claim 16 and claim 24).

6. Optional solvent and hydration excipient limitations

   • Organic solvent examples: dependent claims specify methylene chloride (claim 3).
   • Solvent removal method: dependent claim specifies evaporation under reduced pressure (claim 4).
   • Hydration aqueous solution includes disaccharide/polysaccharide: lactose or trehalose (claims 5–7).

How broad is the claimed “hydro-monobenzoporphyrin” coverage?

Claim 8 (method) / claim 19 (composition) is the chemical scope engine. It captures a genus defined by:

• A Gp scaffold (formulae 1–6 in FIG. 1) and allowance for metalated or labeled forms.
• Variable substituents R1/R2 chosen from a set that includes carbalkoxy (2–6C), sulfonyls, aryl groups, cyano, and a carbamoyl-like unit (--CONR5CO--).
• R3 defined as carboxyalkyl (2–6C) and salts/amides/esters/acylhydrazones, or alkyl.
• R4 defined via aldehyde/alcohol-related and substituted vinyl-derivatization derived groups, plus a conjugated second tetrapyrrole nucleus (1–3 tetrapyrrole-type nucleus with linking through a “L” moiety).

Implication for design-around A competitor can reduce infringement risk only by changing at least one gating element: lipid system (drop EPG or DMPC), photosensitizer class (use a different photosensitizer not within the Gp genus), stoichiometric ratio, process temperature relative to Tg, or target particle size above the claimed limits.

How do the independent claims constrain the manufacturing process?

Method claim 1: “below Tg hydration” + “below Tg size reduction” + <300 nm

Infringement requires all limitations:

• Liposomes with therapeutically acceptable amount of hydro-monobenzoporphyrin Gp
• Lipid mixture: EPG + DMPC
• Photosensitizer:phospholipid molar ratio ≥ 1:7.0
• Organic solvent combination step
• Solvent removal to yield photosensitizer:phospholipid complex
• Hydration at temperature below glass transition temperature (Tg) of the complex to form coarse liposomes
• Homogenization or particle size reduction to <300 nm also performed below Tg

Key scope lever: the Tg-relative constraints convert the claim from an ordinary formulation patent to a process-parameter patent. Many generic or formulation substitutes can match end particle size, lipid composition, and ratio, but still avoid infringement by conducting hydration or size reduction above Tg.

Dependent method claims: what they narrow

• Claim 2: ratio about 1:8.0 or more phospholipid (tighter ratio window).
• Claim 3: solvent specifically methylene chloride.
• Claim 4: solvent removal evaporation under reduced pressure.
• Claims 5–7: aqueous hydration includes disaccharide/polysaccharide, specifically lactose or trehalose, with a defined concentration ratio (10–20:0.5–6.0 relative units as recited).
• Claim 12: photosensitizer is BPD-MA.
• Claims 13–14: hydration and homogenization steps accomplished at ≤ room temperature.
• Claims 15–16: additional particle-size ceilings (<250 nm, <220 nm).

What formulations are protected by US 5,707,608?

Composition claim 17: 150–300 nm liposomes with EPG/DMPC and ratio ≥ 1:7.0

Composition claim 17 is a product-by-parameters claim tied to:

• Particle size about 150 to 300 nm
• Liposomes comprising:
  • therapeutic amount of photosensitizer
  • phospholipid mixture: EPG and DMPC
• Molar ratio photosensitizer:phospholipids about 1:7.0 or more phospholipid

Dependent composition claims add product specificity

• Claim 18: ratio about 1:8.0 or more phospholipid.
• Claims 19–22: Gp structural coverage (FIG. 1 formulae 1–6) plus substituent genus limits; and/or each R3 is carboxyalkyl (or salt/amide/ester/acylhydrazone); each R1/R2 carbalkoxy (2–6C).
• Claim 23: photosensitizer is BPD-MA.
• Claim 24: particle size below about 220 nm.

Design-around implication If a generic manufacturer uses the same photosensitizer class but changes particle size outside 150–300 nm (or outside <220 nm for the narrower dependent claim), or changes EPG/DMPC ratio/identity, infringement risk drops.

How does US 5,707,608 overlap with broader liposomal photosensitizer IP?

Without additional document-set context (continuations, sister patents, and the patent family for US 5,707,608), the most reliable statement is that US 5,707,608 is structurally centered on one manufacturability route (complex formation, hydration below Tg, sizing below Tg) and one lipid system (EPG + DMPC) for a specific photosensitizer genus (hydro-monobenzoporphyrins including BPD-MA). Any broader IP around liposomes or PDT photosensitizers likely covers either:

• different lipid compositions,
• different photosensitizer drugs,
• different particle-size targets,
• different manufacturing parameters (above Tg processes),
• different excipients or lyophilization/form factor.

For business decisions, the operative question is whether your target product will fall inside the hard claim fences:

• EPG + DMPC
• Gp genus including BPD-MA
• ratio ≥ 1:7.0
• particle-size constraints (150–300 nm for composition claim; <300/<250/<220 for method)
• hydration and homogenization performed below the photosensitizer:phospholipid complex Tg

What is the enforceability and expiration profile for US 5,707,608?

US 5,707,608 is a U.S. patent issued in the era where term typically ran to roughly 20 years from earliest non-provisional effective filing, subject to adjustments. The practical result for licensing and freedom-to-operate is that product-market risks depend on whether:

• any priority/continuation or related family patents extend protection,
• regulatory exclusivity (if any) blocks earlier launches irrespective of patent term.

However, without the application’s earliest priority date, and without the family’s adjustment/terminal disclaimers dataset, an expiration-year conclusion cannot be stated accurately for this specific number.

What generic entry risks exist given these claim fences?

Risk is highest when a competitor’s product is effectively a “process-adapted copy”:

• same or functionally equivalent hydro-monobenzoporphyrin (including BPD-MA)
• same EPG + DMPC lipid mixture
• same photosensitizer:phospholipid ratio window (≥1:7.0; potentially 1:8.0)
• same particle-size target (150–300 nm, or <220 nm)
• performed below Tg for hydration and size reduction

Risk is reduced by any of the following:

• replacing EPG and/or DMPC with different phospholipids,
• using a photosensitizer outside the Gp genus/formula set (including avoiding the specific substituted pattern captured in claims 8/19),
• targeting particle size outside the claim bands,
• conducting hydration and/or sizing at/above the complex’s Tg (especially if you avoid the “below Tg” condition as a documented process parameter).

What patent litigation affects US 5,707,608?

No litigation docket, venue, or court disposition can be reliably tied to US 5,707,608 from the information provided. Litigation impact depends on:

• whether US 5,707,608 was asserted in specific cases,
• whether it was narrowed, stayed, invalidated, or settled.

Commercial landscape: which product does this map to?

The claim architecture is characteristic of liposomal BPD-type photosensitizers used in photodynamic therapy (PDT), but a precise mapping to a named FDA-approved product, Orange Book listings, and current competitors cannot be completed from the supplied dataset.

Key Takeaways

• US 5,707,608 protects a specific liposomal PDT formulation build: hydro-monobenzoporphyrin (Gp) including BPD-MA in EPG + DMPC at ≥1:7.0 photosensitizer:phospholipid ratio.
• The method claims are anchored on process temperatures relative to the complex’s glass transition temperature, requiring hydration below Tg and homogenization/size reduction below Tg to reach <300 nm.
• Composition claims protect 150–300 nm liposomes (and narrower bands via dependent claims, including <220 nm) with the same lipid system and ratio.
• Design-around leverage is concentrated in the hard fences: lipid identity, photosensitizer genus, ratio, particle-size endpoint, and the below-Tg process parameter.

FAQs

1) Does US 5,707,608 cover liposomes made by thin-film hydration at room temperature without measuring Tg?
If hydration and sizing are not performed “below the glass transition temperature of the photosensitizer:phospholipid complex,” the method claim 1 limitations are not met.

2) If a product uses EPG/DMPC and BPD-MA but targets 320 nm particles, does it avoid infringement?
It avoids the <300 nm constraint in method claim 1 and the 150–300 nm constraint in composition claim 17; dependent claims add tighter ceilings.

3) What is the most direct claim for protecting the end product?
Composition claim 17.

4) Can changing the organic solvent used in step (a) avoid the method claim?
The method claim 1 requires an organic solvent but does not limit it to methylene chloride; dependent claim 3 specifically narrows to methylene chloride.

5) Do lactose or trehalose matter for infringement of the broadest claims?
No. Lactose/trehalose limitations appear only in dependent claims (5–7). The broadest method/composition claims focus on photosensitizer, EPG/DMPC, ratio, Tg-relative steps (method), and particle size.